UPDATE: Cantor Fitzgerald Reiterates Synergy Pharmaceuticals at Buy on Late Breaker Announcement
In a report published by Cantor Fitzgerald, analyst Irina Rivkind reiterated a Buy rating and $13 price target on Synergy Pharmaceuticals (NASDAQ: SGYP).
Cantor Fitzgerald reported that, “DDW Late Breaker announcement is an important catalyst for SGYP: Synergy announced that it would present full study results from its Phase IIb/ III chronic constipation (CC) trial of plecanatide in a late-breaking clinical abstract at Digestive Disease Week (DDW) on Tuesday, May 21. The poster will be presented by a well-known key opinion leader, which should enhance plecanatide visibility amongst gastroenterologists. We view this news as an important catalyst for the stock.”
Shares of Synergy Pharmaceuticals closed at $6.01 on Thursday.
Latest Ratings for SGYP
|Oct 2014||Cantor Fitzgerald||Maintains||Buy|
|Nov 2013||Canaccord Genuity||Reiterates||Buy|
|Nov 2013||Aegis Capital||Reiterates||Buy|
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.